CUMYL-THPINACA

CUMYL-THPINACA is a synthetic cannabinoid that is used as an active ingredient in synthetic cannabis products. It is a potent agonist for the CB1 receptor, with a binding affinity of 5.5 nM, making it approximately 33 times more potent than THC. CUMYL-THPINACA was first identified in a herbal product in Hungary in 2015, and has since been identified in numerous other countries.

Chemistry

CUMYL-THPINACA is a member of the cannabinoid class of psychoactive substances. It is structurally related to other synthetic cannabinoids such as CUMYL-PINACA, but differs in that it has a tetrahydroindazole base instead of an indazole base.

Pharmacology

CUMYL-THPINACA acts as a potent agonist for the CB1 receptor, with a binding affinity of 5.5 nM. This makes it approximately 33 times more potent than THC, the primary psychoactive compound in cannabis. The exact mechanisms of action and metabolic pathways of CUMYL-THPINACA are not fully understood, but it is believed to act in a similar manner to other synthetic cannabinoids.

Effects

The effects of CUMYL-THPINACA can vary widely depending on the dose and individual's tolerance. Common effects include relaxation, euphoria, altered perception, and in some cases, hallucinations. However, CUMYL-THPINACA can also cause a number of adverse effects, including anxiety, paranoia, and in severe cases, seizures.

Legal Status

CUMYL-THPINACA is illegal in many countries, including the United States, where it is classified as a Schedule I controlled substance. It is also illegal in many European countries, including the United Kingdom, where it is classified as a Class B drug.

See Also

• Synthetic cannabinoids
• CUMYL-PINACA
• CB1 receptor
• THC

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia